Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.33 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268929 | 0.92 | MGLL (0.38) | MGLLNTRK1HCRTR1HCRTR2PIK3CA | |
| SCHEMBL5265982 | 0.81 | SCD5 (0.43) | MGLLNTRK1 | |
| SCHEMBL5266809 | 0.80 | MGLL (0.45) | MGLLNTRK1PIK3CAPIK3CDPIK3R2 | |
| SCHEMBL2919121 | 0.80 | HCRTR1 (0.40) | MGLLNTRK1HCRTR1HCRTR2PIK3CA | |
| SCHEMBL14529765 | 0.80 | PDE4B (0.37) | MGLLNTRK1KDM1A | |
| SCHEMBL2921813 | 0.79 | NTRK1 (0.51) | MGLLNTRK1PIK3CAPIK3CDKDM1A | |
| SCHEMBL2916328 | 0.79 | BRD4 (0.41) | MGLLNTRK1HCRTR1HCRTR2PIK3CA | |
| SCHEMBL2918390 | 0.79 | NTRK1 (0.46) | MGLLNTRK1 | |
| SCHEMBL2918346 | 0.78 | CFTR (0.42) | MGLLNTRK1HCRTR1HCRTR2KDM1A | |
| SCHEMBL2918250 | 0.78 | RPA1 (0.52) | NTRK1RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | ADORA2A 472/4885ADORA1 127/4885MGLL 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.